148 related articles for article (PubMed ID: 34610104)
21. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
[TBL] [Abstract][Full Text] [Related]
22. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
23. Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.
Al-Khabori M; Minden MD; Yee KW; Gupta V; Schimmer AD; Schuh AC; Xu W; Brandwein JM
Leuk Lymphoma; 2010 Jan; 51(1):61-5. PubMed ID: 20017600
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
[TBL] [Abstract][Full Text] [Related]
25. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
[TBL] [Abstract][Full Text] [Related]
26. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
[TBL] [Abstract][Full Text] [Related]
27. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
28. Bony morbidity in children treated for acute lymphoblastic leukemia.
Strauss AJ; Su JT; Dalton VM; Gelber RD; Sallan SE; Silverman LB
J Clin Oncol; 2001 Jun; 19(12):3066-72. PubMed ID: 11408503
[TBL] [Abstract][Full Text] [Related]
29. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
30. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.
te Winkel ML; Pieters R; Hop WC; de Groot-Kruseman HA; Lequin MH; van der Sluis IM; Bökkerink JP; Leeuw JA; Bruin MC; Egeler RM; Veerman AJ; van den Heuvel-Eibrink MM
J Clin Oncol; 2011 Nov; 29(31):4143-50. PubMed ID: 21947829
[TBL] [Abstract][Full Text] [Related]
31. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.
Ram R; Wolach O; Vidal L; Gafter-Gvili A; Shpilberg O; Raanani P
Am J Hematol; 2012 May; 87(5):472-8. PubMed ID: 22388572
[TBL] [Abstract][Full Text] [Related]
32. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
33. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
34. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Moghrabi A; Levy DE; Asselin B; Barr R; Clavell L; Hurwitz C; Samson Y; Schorin M; Dalton VK; Lipshultz SE; Neuberg DS; Gelber RD; Cohen HJ; Sallan SE; Silverman LB
Blood; 2007 Feb; 109(3):896-904. PubMed ID: 17003366
[TBL] [Abstract][Full Text] [Related]
35. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
[TBL] [Abstract][Full Text] [Related]
36. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
37. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
[TBL] [Abstract][Full Text] [Related]
38. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
Labar B; Suciu S; Willemze R; Muus P; Marie JP; Fillet G; Berneman Z; Jaksic B; Feremans W; Bron D; Sinnige H; Mistrik M; Vreugdenhil G; De Bock R; Nemet D; Gilotay C; Amadori S; de Witte T;
Haematologica; 2010 Sep; 95(9):1489-95. PubMed ID: 20378563
[TBL] [Abstract][Full Text] [Related]
39. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
[TBL] [Abstract][Full Text] [Related]
40. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).
Bona K; Blonquist TM; Neuberg DS; Silverman LB; Wolfe J
Pediatr Blood Cancer; 2016 Jun; 63(6):1012-8. PubMed ID: 26913850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]